Latest Conference Coverage

Next Steps in Alzheimer Disease Research: Clive Ballard, MD

Clive Ballard, MD, discussed up-and-coming technologies for remote risk assessment, among other data presented at this year’s AAIC meeting.

Most Patients Report Positive Lemborexant Treatment Effect in Insomnia

Data presented at SLEEP 2021 from Study 303 suggest that long-term use of lemborexant is well received by patients, who reported that the agent helped them fall asleep and improved total sleep time.

AHS 2021 Takeaways and the State of Migraine Research: Richard B. Lipton, MD

The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.

Treating Migraine With External Trigeminal Nerve Stimulation

Deena Kuruvilla, MD, the medical director of the Westport Headache Institute spoke to the potential of e-TNS in the treatment of migraine overall and which gaps in care that it might fill.

Clinical Takeaways From INP104 Data in Migraine: Sheena K. Aurora, MD

The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.

Greatest Unmet Needs in Sleep Disorder Care: Asim Roy, MD

The medical director of the Ohio State Sleep Medicine Institute provided insight on areas within sleep disorder care that need improvement, including the diagnostic process.

Daridorexant Shows Efficacy as Insomnia Therapy With Evidence of No Withdrawal Effects

The Idorsia dual orexin receptor antagonist was accepted by the FDA for review in March 2021 and has shown efficacy in a number of SLEEP 2021 poster presentations.

FT218’s Effect on BMI Regardless of Stimulant Use: Asim Roy, MD

The medical director of the Ohio State Sleep Medicine Institute discussed the effect of FT218 in treating narcolepsy regardless of stimulant use, as well as its weight-related benefits it brings.

Future Areas of Progress for Sleep Disorder Care: Asim Roy, MD

The medical director of the Ohio State Sleep Medicine Institute detailed the progress made within the sleep disorder field in recent years and where it can turn to next.

NeuroVoices: Michael J. Thorpy, MD, on FT218, State of Current Sleep Care

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational FT218 brings to the growing pipeline.

Novel Approaches to Challenges in Treating Migraine: Carrie Dougherty, MD, FAHS

CBT-I Headlines AASM Guidelines for Chronic Insomnia

The task force assessed 6 total interventions, all of which received conditional recommendations aside from cognitive behavioral therapy for insomnia, which was strongly recommended.

Solriamfetol Efficacious, Easily Titrated in Patients Initiating Treatment for Narcolepsy

Results from the START study of medication switching in narcolepsy were presented at the 2021 SLEEP Annual Meeting.

Telemedicine Produces Meaningful Migraine Improvement, Galcanezumab Shows No Wearing Effect, CGRPs All Significant Improve MMDs

Neurology News Network for the week ending June 12, 2021.

Pitolisant Further Demonstrates Clinical Benefit on Excessive Daytime Sleepiness, Cataplexy

The FDA-approved agent demonstrated meaningful reduction in the frequency of cataplexy attacks in adults with narcolepsy, including patients with a high symptom burden.

FT218 Efficacious in Treating Narcolepsy Subtypes

Data presented at SLEEP 2021 also showed the treatment was associated with significant weight loss and reduction in BMI compared to placebo.

Investigating INP104 for Migraine Treatment: Carrie Dougherty, MD, FAHS

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed further research to be conducted with the nasal delivery of DHE.

Clinically Meaningful Improvements in Migraine Achievable With Synchronous Telemedicine

The findings support previous data that showed no differences between telemedicine and traditional consultations in HIT-6 assessment scores over a long-term period.

Concomitant Use of Ubrogepant With CGRP Monoclonal Antibodies: Richard B. Lipton, MD

The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.

Rimegepant Achieves Migraine Prevention After 1 Week of Treatment

A post-hoc analysis of the phase 2/3 trial of rimegepant revealed early and sustained efficacy compared to placebo, with significant reductions in weekly migraine days.

Nasal Delivery of DHE for Migraine: Carrie Dougherty, MD, FAHS

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the advantages of INP104 over other forms of dihydroergotamine.

New Migraine Burden Index Proves Accurate, Strongly Correlates With Patient Satisfaction

Investigators conducted a 9-month study that demonstrated the correlation of the MBI, calculated as the sum of headache days times the maximum intensity of headache on each headache day, with satisfaction of migraine status.

Despite Slight Differences, Preventive Migraine Therapies Demonstrate High Efficacy

Researchers used a connected network of studies that were generally well balanced in terms of key baseline characteristics, such as baseline MMD and use of prior therapies, to compare preventive treatments.

NeuroVoices: Andrew Blumenfeld, MD, on a Combination Approach to Treating Chronic Migraine

The director for the Headache Center of Southern California discussed his research presented at AHS 2021 which evaluated a combination of onabotunlinumtoxinA and CGRPs in patients with chronic migraine.

Fremanezumab Yields Monthly Migraine and Headache Reductions in Real-World Setting

Recent data presented at the AHS annual meeting showed clinically meaningful improvements in MMD and MHD in patients with both chronic and episodic migraine.

No Significant Wearing Off Effect With Galcanezumab for Migraine Prevention

A post-hoc analysis of 4 clinical trials of galcanezumab found no differences between dose groups of galcanezumab or placebo in rates of ‘wearing off’ effect.

Applying Data on CGRP, OnabotulinumtoxinA Combination to Clinical Practice: Andrew Blumenfeld, MD

The director of the Headache Center of Southern California provided insight on how a layered treatment approach to chronic migraine can be directly implemented into clinical care.

Advantages of Migraine Buddy App: Richard B. Lipton, MD

The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.

Ubrogepant Demonstrates Safety, Efficacy in Treating Perimenstrual Migraine

Absence of photophobia, phonophobia, and nausea were achieved in a similar percentage of perimenstrual and non-perimenstrual ubrogepant-treated attacks.

Higher Dose OnabotulinumtoxinA Safe for Chronic Migraine in Real-World Study

These real-world findings confirm that a 156- to 195-unit dose of onabotulinumtoxinA is efficacious and safe, consistent with findings from the PREEMPT clinical trials.